Centre for Biomedicine and Medical Technology Mannheim, Research Division Cardiovascular Physiology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Hypertension. 2013 Jan;61(1):151-9. doi: 10.1161/HYPERTENSIONAHA.112.197566. Epub 2012 Nov 26.
KCNQ channels have been identified in arterial smooth muscle. However, their role in vasoregulation and chronic vascular diseases remains elusive. We tested the hypothesis that KCNQ channels contribute to periadventitial vasoregulation in peripheral skeletal muscle arteries by perivascular adipose tissue and that they represent novel targets to rescue periadventitial vascular dysfunction. Two models, spontaneously hypertensive rats and New Zealand obese mice, were studied using quantitative polymerase chain reaction, the patch-clamp technique, membrane potential measurements, myography of isolated vessels, and blood pressure telemetry. In rat Gracilis muscle arteries, anticontractile effects of perivascular fat were inhibited by the KCNQ channel blockers XE991 and linopirdine but not by other selective K(+) channel inhibitors. Accordingly, XE991 and linopirdine blocked noninactivating K(+) currents in freshly isolated Gracilis artery smooth muscle cells. mRNAs of several KCNQ channel subtypes were detected in those arteries, with KCNQ4 channels being dominant. In spontaneously hypertensive rats, the anticontractile effect of perivascular fat in Gracilis muscle arteries was largely reduced compared with Wistar rats. However, the vasodilator effects of KCNQ channel openers and mRNA expression of KCNQ channels were normal. Furthermore, KCNQ channel openers restored the diminished anticontractile effects of perivascular fat in spontaneously hypertensive rats. Moreover, KCNQ channel openers reduced arterial blood pressure in both models of hypertension independent of ganglionic blockade. Thus, our data suggest that KCNQ channels play a pivotal role in periadventitial vasoregulation of peripheral skeletal muscle arteries, and KCNQ channel opening may be an effective mechanism to improve impaired periadventitial vasoregulation and associated hypertension.
KCNQ 通道已在动脉平滑肌中被鉴定出来。然而,它们在血管调节和慢性血管疾病中的作用仍然难以捉摸。我们假设 KCNQ 通道通过血管周围脂肪组织参与外周骨骼肌动脉的血管周围调节,并且它们是挽救血管周围血管功能障碍的新靶点。使用定量聚合酶链反应、膜片钳技术、膜电位测量、分离血管的肌电图和血压遥测技术研究了自发性高血压大鼠和新西兰肥胖小鼠两种模型。在大鼠股薄肌动脉中,血管周围脂肪的抗收缩作用被 KCNQ 通道阻滞剂 XE991 和利诺吡啶抑制,但其他选择性 K(+)通道抑制剂则没有。因此,XE991 和利诺吡啶阻断了新鲜分离的股薄肌动脉平滑肌细胞中不激活的 K(+)电流。这些动脉中检测到几种 KCNQ 通道亚型的 mRNA,其中 KCNQ4 通道占主导地位。与 Wistar 大鼠相比,自发性高血压大鼠股薄肌动脉血管周围脂肪的抗收缩作用大大降低。然而,KCNQ 通道开放剂的血管舒张作用和 KCNQ 通道的 mRNA 表达正常。此外,KCNQ 通道开放剂恢复了自发性高血压大鼠中血管周围脂肪的抗收缩作用的减弱。此外,KCNQ 通道开放剂独立于神经节阻断作用降低了两种高血压模型的动脉血压。因此,我们的数据表明,KCNQ 通道在周围骨骼肌动脉的血管周围调节中发挥关键作用,KCNQ 通道开放可能是改善受损血管周围调节和相关高血压的有效机制。